Autobahn Therapeutics, Inc.’s Post

Excited to share some client news - Autobahn Therapeutics, Inc. has raised $100 million for its Series C financing, and will use the funds to advance its therapies for depression and biopolar depression disorder. This is a huge area of need, and the company's drugs have an interesting backstory: a link discovered by physicians in the 1950s between thyroid hormone drugs and anti-depressant effects. However off-target activities and side effects limited their use for this purpose. To overcome these issues, Autobahn has developed an oral, potent and selective thyroid hormone beta receptor agonist designed to enhance the CNS benefits of thyroid hormone biology while also reducing the peripheral liabilities of prior treatments. Hoping they see continued success in clinical trials with their drugs! #depression #bipolar #CNS #funding #biotech #venturecapital

💙 Facing a breast cancer diagnosis can feel very isolating but with Wendy Muise and her team at Breast Buds Inc by your side during your journey, you know you aren't alone! The app helps connect people, from diagnosis to after-care, with critical peer support and valuable resources. 💙 Learn more from Wendy and the rest of cohort 5 during their live pitches at Demo Day, June 5 from 4-7 pm at Edmonton Unlimited! Register Here! 👉 https://lnkd.in/g-Q2EUvs CSW is a tech start-up accelerator focused on supporting business development while driving positive social impact. A collaborative program by design, it is poised to demonstrate the tremendous potential of leveraging entrepreneurship, innovation, community partners and key stakeholders to deliver valuable, quantifiable impact towards community safety and wellness, while also contributing to the innovation ecosystem and economy of Alberta. www.cswaccelerator.com We are proudly part of the Alberta Scaleup and Growth Accelerator Program that is run by a consortium led by Alberta Innovates. The consortium, which also includes Technology and Innovation, Edmonton Unlimited, The Opportunity Calgary Investment Fund and Prairies Economic Development Canada I Développement économique Canada pour les Prairies, allocated $35 million over three years to retain business accelerators. It’s part of an overall government goal to help create 20,000 jobs and increase technology firm revenue to $5 billion by 2030. #breastcancer #socialimpact #techforgood #cswaccelerator

It's been an exciting year in clinical advancements in #ovariancancer. Catch this replay of today's update session from our 3rd Annual Virtual Global Partner Meeting here: https://loom.ly/V-bQq-I

Join me this Thursday to learn more about the basics of lymphedema therapy!

Gain insights at #ELCC24 as we present a 4-year exploratory analysis from lead author Professor Martin Reck; how is the quality of survival for patients with metastatic #NSCLC affected by dual #immunotherapy + chemo vs chemo?

Judy George from MedPage Today reports on new guidelines for defining Alzheimer's disease based on biological markers, developed by a workgroup from the Alzheimer's Association®. These criteria include categorizing biomarkers and revising how the disease's progression is understood. According to Clifford Jack Jr., MD, and his colleagues at the Mayo Clinic, Alzheimer's disease is identifiable through abnormal biomarkers even before cognitive symptoms appear, a point of debate within the Alzheimer's community. Jack emphasizes that the pathology linked with Alzheimer's starts showing in the brain 15 to 20 years before symptoms arise, making biomarker evidence crucial for diagnosing the disease, even in asymptomatic individuals. The revised guidelines outline three types of biomarkers: core biomarkers specific to Alzheimer's, those important to the disease but not specific, and markers reflecting commonly associated conditions. The committee underscores that an abnormal result in core biomarkers like amyloid PET scans or specific cerebrospinal fluid markers is sufficient to diagnose Alzheimer's disease. However, these guidelines are not yet clinical practice standards and are meant to aid in research and evaluation of symptomatic patients rather than those without cognitive impairment. Formal clinical guidelines for testing and treatment are anticipated from the Alzheimer's Association in the future. #Alzheimers #biomarkers #diagnosis #ENDALZ https://lnkd.in/ghDFECc5

I cannot even put into words, the power, courage, and perseverance that Peter Mang and Katie Mang continue to model in a world where #cancer hits close to home. If you wanna learn more about Pete and Katie‘s journey, or the impacts of glioblastoma and how you can help, follow Go With The Good Foundation connect with Katie Mang and Julie Wilson. #glioblastoma #kindnessmatters #helpingothers #womenwholead

#Cancer: It's not over when it's over. Becoming a "cancer survivor" instead of an active treatment patient can be a scary, lonely, uncoordinated time of transition. Being a long-term cancer survivor is full of unknowns and symptoms that may be 'normal' or may be late effects. And there are late-risk effects from prior treatments... but what screening is needed and who coordinates that?? If YOU are a #healthcare #provider working with #survivorship patients, #TheCSPN is here for you. We provide peer support for comprehensive, equitable, high-quality survivorship care. Learn more about our free membership and resources today: www.TheCSPN.org

It's a fact: Healthcare professionals of all types are seeing more cancer survivors in their practices. That is terrific! People with cancer are being treated with new agents and living longer than ever before. They are also living with chronic cancer, maintenance treatments, and the lifelong effects and impact of cancer and it's treatments (physical, functional, psychological, relationships, financial, and more). It's a fact: #Healthcare professionals of all types get little to no training on caring for #cancer #survivors. Even for #oncology specialists 'Survivorship' is a new and expanding field. The Cancer Survivorship Provider Network (www.TheCSPN.org) is a secure, online platform where those in healthcare, #supportiveservices, #research, and #advocacy organizations can come together, share resources, and learn from one another. Membership in this provider-facing, international, grassroots, nonprofit organization is free. Come learn with us.

UK Markey Cancer's Dr. Guan-Yu Xiao has secured a $747,000 grant from the National Cancer Institute to study lung cancer metastasis. His work focuses on lung adenocarcinoma, aiming to understand the cellular processes that drive cancer spread. This research could lead to new treatments and tackle resistance to current therapies. Dr. Xiao's findings on the EMT process and the Rab6A protein could revolutionize how we approach cancer treatment. Learn more about this groundbreaking study: https://bit.ly/3S4Nsse #CancerResearch #LungCancer #UKResearch #MedicalInnovation #Healthcare